Learning Objectives
- Discuss the emerging role of SGLT2 inhibitors as a strategy for individualizing management of hyperglycemia in diabetes.
- Discuss the cardiovascular outcome trials in diabetes.
- Discuss the CDA guidelines on SGLT2 inhibitors and cardiovascular risk.
- Discuss the practical implications and side effects of SGLT2 inhibitors.
Agenda
Click to See Video in Chapters
Chairs
Lawrence A Leiter
MD, FRCPC, FACP, FACE, FAHA
Endocrinologist, St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences, University of Toronto
Ronald M Goldenberg
MD, FRCPC, FACE
Consultant Endocrinologist,
New York General Hospital & LMC Diabetes & Endocrinology,
Thornhill, Ontario
Faculty
David Z I Cherney
MD CM, PhD, FRCPC
Nephrologist, University Health Network and Mount Sinai Hospitals
Associate Professor of Medicine, University of Toronto
Amir K Hanna
MB BCh, FRCPC, FACP
Endocrinologist, St. Michael’s Hospital
Professor Emeritus, Department of Medicine, University of Toronto
Subodh Verma
MD, PhD, FRCSC, FAHA
Division of Cardiac Surgery, St. Michael’s Hospital
Professor Surgery and Pharmacology & Toxicology, University of Toronto